NImmune Biopharma has entered into a strategic partnership with BioTherapeutics, a clinical-stage biotech company based in Virginia, to accelerate the development of next-generation precision medicines targeting inflammatory and autoimmune diseases. This collaboration is poised to leverage BioTherapeutics’ advanced computational modeling, regulatory expertise, and unique animal models to fast-track NImmune Biopharma’s pipeline, particularly its LANCL immunoregulatory […]
AbbVie Inc. (NYSE: ABBV), a global biopharmaceutical leader, has announced the completion of its acquisition of Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company, for a total consideration of $137.5 million. This strategic acquisition underscores AbbVie’s commitment to expanding its robust immunology portfolio. Acquisition Details and Future Prospects The acquisition deal, which was first […]
AbbVie Inc. (NYSE: ABBV) and Landos Biopharma, Inc. (NASDAQ: LABP) have announced a landmark agreement, marking a strategic move in the biopharmaceutical sector focused on the development of novel treatments for autoimmune diseases. The definitive agreement outlines AbbVie’s acquisition of Landos, a clinical-stage biopharmaceutical company renowned for its innovative approach to creating oral therapeutics for […]
